Erschienen in:
Open Access
01.12.2012 | Poster presentation
Regulation of macrophage-mediated chronic inflammation by JAK inhibitors
verfasst von:
Anna Yarilina, Kai Xu, Chunhin Chan, Lionel B Ivashkiv
Erschienen in:
Arthritis Research & Therapy
|
Sonderheft 1/2012
Einloggen, um Zugang zu erhalten
Excerpt
Small molecule inhibitors of the Janus kinases (JAK) have been developed as anti-inflammatory and immunosuppressive agents and are currently subjects of clinical trials. Tofacitinib/CP-690,550 (more potent in inhibiting JAK3 and JAK1) and Ruxolitinib/INCB-018424 (selective inhibitor of JAK1/2) have demonstrated clinical efficacy in rheumatoid arthritis (RA), however, the exact mechanisms that mediate the inhibitory effects of these compounds are not known. …